Novartis announces the company’s financial results for the second quarter and first half of 2025.Novartis announces the company’s financial results for the second quarter and first half of 2025.
Showing 97 results
-
Zykadia®
( ceritinib )Oncology -
Zortress®/Certican®
( everolimus )Immunology and Dermatology -
Zolgensma®
( onasemnogene abeparvovec )Gene therapy -
Xolair®
( omalizumab )Immunology and Dermatology -
Votrient®
( pazopanib )Oncology -
Vijoice®
( alpelisib )Oncology -
Ultibro® Breezhaler®
( indacaterol, glycopyrronium bromide )Respiratory -
Tykerb®/Tyverb®
( lapatinib )Oncology -
Trileptal®
( oxcarbazepine )NeuroscienceAvailable in